GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » Price-to-Free-Cash-Flow

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Apr. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-04-26), Conatus Pharmaceuticals's share price is $0.56. Conatus Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2020 was $-0.48. Hence, Conatus Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Conatus Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

CNAT's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.76
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Conatus Pharmaceuticals's Free Cash Flow per Share for the three months ended in Mar. 2020 was $-0.08. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.48.


Conatus Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Conatus Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conatus Pharmaceuticals Price-to-Free-Cash-Flow Chart

Conatus Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - 5.91 - - -

Conatus Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Conatus Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Conatus Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conatus Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conatus Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Conatus Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Conatus Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Conatus Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.56/-0.48
=N/A

Conatus Pharmaceuticals's Share Price of today is $0.56.
Conatus Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Conatus Pharmaceuticals  (NAS:CNAT) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Conatus Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Conatus Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Headlines

From GuruFocus

Histogen to Present at BIO CEO & Investor Conference

By PRNewswire PRNewswire 02-06-2020